{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:56:15Z","timestamp":1776974175001,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bone.2021.116243","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T12:09:54Z","timestamp":1635509394000},"page":"116243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe"],"prefix":"10.1016","volume":"154","author":[{"given":"Roger","family":"von Moos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Massey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouchka","family":"Seesaghur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.116243_bb0005","first-page":"67","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body","year":"2017"},{"issue":"4","key":"10.1016\/j.bone.2021.116243_bb0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000358258","article-title":"Management of bone metastases in patients with castration-resistant prostate cancer","volume":"92","author":"Cathomas","year":"2014","journal-title":"Urol. Int."},{"issue":"2","key":"10.1016\/j.bone.2021.116243_bb0015","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/j.clgc.2017.09.015","article-title":"Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey","volume":"16","author":"Drudge-Coates","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.bone.2021.116243_bb0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"issue":"Suppl 3","key":"10.1016\/j.bone.2021.116243_bb0025","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.bone.2021.116243_bb0030","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.bone.2021.116243_bb0035","first-page":"234","article-title":"Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors","volume":"2","author":"Major","year":"2005"},{"issue":"8","key":"10.1016\/j.bone.2021.116243_bb0040","first-page":"879","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.bone.2021.116243_bb0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10198-015-0716-7","article-title":"Health resource utilization associated with skeletal-related events: results from a retrospective european study","volume":"17","author":"Body","year":"2016","journal-title":"Eur. J. Health Econ."},{"issue":"2","key":"10.1016\/j.bone.2021.116243_bb0050","first-page":"40","article-title":"Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective - prospective observational study - a cohort from 4 European countries","volume":"3","author":"Hoefeler","year":"2014"},{"issue":"2","key":"10.1016\/j.bone.2021.116243_bb0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med. Care"},{"issue":"4","key":"10.1016\/j.bone.2021.116243_bb0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bone.2021.116243_bb0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3111\/13696998.2014.890937","article-title":"Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases","volume":"17","author":"Hagiwara","year":"2014","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.bone.2021.116243_bb0070","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2013.779921","article-title":"Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study","volume":"16","author":"Hechmati","year":"2013","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.bone.2021.116243_bb0075","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3111\/13696998.2016.1150852","article-title":"Cost of skeletal complications from bone metastases in six European countries","volume":"19","author":"Pereira","year":"2016","journal-title":"J. Med. Econ."},{"issue":"9768","key":"10.1016\/j.bone.2021.116243_bb0080","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.bone.2021.116243_bb0085","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"35","key":"10.1016\/j.bone.2021.116243_bb0090","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bone.2021.116243_bb0095","first-page":"3497","article-title":"Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid","volume":"21","author":"von Moos","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bone.2021.116243_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bone.2021.116243_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2021.116243_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.4360","article-title":"Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States","volume":"27","author":"Butler","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.bone.2021.116243_bb0115","first-page":"103","article-title":"Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer","volume":"22","author":"Hagiwara","year":"2014","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.bone.2021.116243_bb0120","first-page":"2175","article-title":"Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany","volume":"28","author":"Link","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bone.2021.116243_bb0125","first-page":"1349","article-title":"Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US","volume":"10","author":"McGrath","year":"2018"},{"key":"10.1016\/j.bone.2021.116243_bb0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2017.03.031","volume":"79","author":"Schroder","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bone.2021.116243_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100273","article-title":"Patterns of care for patients with metastatic bone disease in solid tumors: a cross-sectional study from Switzerland (SAKK 95\/16)","volume":"21","author":"Mark","year":"2020","journal-title":"J. Bone Oncol."},{"issue":"11","key":"10.1016\/j.bone.2021.116243_bb0140","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bone.2021.116243_bb0145","article-title":"A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","volume":"14","author":"Body","year":"2019"},{"key":"10.1016\/j.bone.2021.116243_bb0150","first-page":"1","article-title":"Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries","volume":"11","author":"von Moos","year":"2018"},{"issue":"2","key":"10.1016\/j.bone.2021.116243_bb0155","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.urology.2012.04.007","article-title":"Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices","volume":"80","author":"Freedland","year":"2012","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.bone.2021.116243_bb0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/0300891619851376","article-title":"Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why","volume":"105","author":"Gallicchio","year":"2019","journal-title":"Tumori"},{"issue":"22","key":"10.1016\/j.bone.2021.116243_bb0165","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1002\/cncr.32414","article-title":"Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"125","author":"Tablazon","year":"2019","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.bone.2021.116243_bb0170","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/cncr.30505","article-title":"Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer","volume":"123","author":"Klaassen","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2021.116243_bb0175","first-page":"38","article-title":"Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: a systematic review of the real world data","volume":"11","author":"Zhang","year":"2018"},{"issue":"9","key":"10.1016\/j.bone.2021.116243_bb0180","first-page":"4019","article-title":"Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals","volume":"28","author":"Drudge-Coates","year":"2020","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.bone.2021.116243_bb0185","first-page":"117","article-title":"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment","volume":"127","author":"Nicolatou-Galitis","year":"2019"},{"key":"10.1016\/j.bone.2021.116243_bb0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bone.2021.116243_bb0195","article-title":"Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: an international perspective and recommendations","volume":"29","author":"Brown","year":"2021"},{"issue":"11","key":"10.1016\/j.bone.2021.116243_bb0205","first-page":"6903","article-title":"Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey","volume":"29","author":"Alzahrani","year":"2021","journal-title":"Support Care Cancer"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221004099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221004099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:05:55Z","timestamp":1757613955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221004099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":40,"alternative-id":["S8756328221004099"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116243","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116243"}}